NCT06788990Phase 2, phase 3Recruiting

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

Study sponsor: Bicara Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-04Estimated
Enrollment · participants650Estimated
Source updated2026-11-19Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.